Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718400 | 0.83 | MEN1 (0.51) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL24718422 | 0.82 | MEN1 (0.55) | MEN1KMT2AALDH1A1 | |
| SCHEMBL24719109 | 0.79 | MEN1 (0.47) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL24718390 | 0.79 | MEN1 (0.50) | MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24718622 | 0.76 | EPHX2 (0.46) | MEN1KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL24719133 | 0.74 | SMN1; SMN2 (0.44) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL24719112 | 0.74 | SMN1; SMN2 (0.44) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL24718657 | 0.74 | SMN1; SMN2 (0.44) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL24718379 | 0.73 | POLB (0.45) | MAPTALDH1A1CHRNA4MCHR1L3MBTL1 | |
| SCHEMBL3580532 | 0.72 | MAPT (0.74) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | UNITED STATES GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | EED, EZH2, ELP1 | MEN1 3534/4885KMT2A 180/4885RAB9A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.